SirThe results of J Cinatl and colleagues show that interferon beta is effective against SARS-CoV—a membrane-enclosed RNA virus—in vitro, when used either alone or in combination with other antiviral drugs.Their results concur with our beliefs that interferon, with its broad-spectrum antiviral activity against RNA viruses, might be useful in the treatment of SARS, either as a monotherapy or plus ribavirin.However, the findings of Ozes and co-workers show that the specific activity (antiviral units/mg) of recombinant human interferon-consensus 1 (IFN-Con1) was ten-fold higher than that of interferon alfa-2a and interferon alfa-2b in vitro. Furthermore, IFN-Con1 increases the ability of or induces natural killer cells to kill target cells to a greater extent than does interferon alfa.Therefore, we suggest that IFN-Con1 and IFN-Con1 plus ribavirin are assessed as potential antiviral drugs for the treatment of SARS with the method used by Cinatl and colleagues.
Authors: Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr Journal: N Engl J Med Date: 2003-04-10 Impact factor: 91.245
Authors: Faryal Khamis; Hanan Al Naabi; Adil Al Lawati; Zaiyana Ambusaidi; Mariam Al Sharji; Umkulthum Al Barwani; Nenad Pandak; Zakariya Al Balushi; Maher Al Bahrani; Issa Al Salmi; Ibrahim Al-Zakwani Journal: Int J Infect Dis Date: 2020-11-09 Impact factor: 3.623